A retrospective feasibility study of biweekly docetaxel in patients with high-risk metastatic castration-naïve prostate cancer

Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017

(2018) Silke Gillessen et al.   EUROPEAN UROLOGY

A retrospective feasibility study of biweekly, reduced-dose docetaxel in Asian patients with castrate-resistant, metastatic prostate cancer

(2017) Hae Su Kim et al.   BMC Urology

Cancer Statistics in Korea: Incidence, Mortality, Survival, and Prevalence in 2014

(2017) Kyu-Won Jung et al.   Cancer Research and Treatment

Androgen Deprivation Therapy (ADT) Plus Docetaxel Versus ADT Alone in Metastatic Non castrate Prostate Cancer: Impact of Metastatic Burden and Long-term Survival Analysis of the Randomized Phase 3 GETUG-AFU15 Trial

(2016) Gwenaelle Gravis et al.   EUROPEAN UROLOGY

Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial

(2016) Nicholas D James et al.   LANCET

Cancer of the prostate: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

(2015) C. Parker et al.   ANNALS OF ONCOLOGY

Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer

(2015) Christopher J. Sweeney et al.   NEW ENGLAND JOURNAL OF MEDICINE

Management of prostate cancer in older patients: updated recommendations of a working group of the International Society of Geriatric Oncology

(2014) Jean-Pierre Droz et al.   LANCET ONCOLOGY

2-weekly versus 3-weekly docetaxel to treat castration-resistant advanced prostate cancer: a randomised, phase 3 trial

(2013) Pirkko-Liisa Kellokumpu-Lehtinen et al.   LANCET ONCOLOGY

Efficacy and Safety of Docetaxel Plus Prednisolone Chemotherapy for Metastatic Hormone-Refractory Prostate Adenocarcinoma: Single Institutional Study in Korea

(2010) Jae-Lyun Lee et al.   Cancer Research and Treatment

Docetaxel Plus Prednisone or Mitoxantrone Plus Prednisone for Advanced Prostate Cancer: Updated Survival in the TAX 327 Study

(2008) Dominik R. Berthold et al.   JOURNAL OF CLINICAL ONCOLOGY

Design and End Points of Clinical Trials for Patients With Progressive Prostate Cancer and Castrate Levels of Testosterone: Recommendations of the Prostate Cancer Clinical Trials Working Group

(2008) Howard I. Scher et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase III Trial of Androgen Ablation With or Without Three Cycles of Systemic Chemotherapy for Advanced Prostate Cancer

(2008) Randall E. Millikan et al.   JOURNAL OF CLINICAL ONCOLOGY